Method Development in Forensic Toxicology.

abstract：:RNA interference (RNAi) has quickly proven to be an immensely useful tool for studying gene function and validation of potential drug targets in almost all organisms that possess the required set of proteins of the interference pathway. In protozoan parasites like Plasmodium, Toxoplasma, Entamoeba, Giardia, Trypanosom...

journal_title：Current pharmaceutical design

authors： Mueller AK,Hammerschmidt-Kamper C,Kaiser A

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Neglected tropical diseases (NTDs) represent a serious problem in a number of countries around the world and especially in Africa and South America, affecting mostly the poor population which has limited access to the healthcare system. The drugs currently used for the treatment of NTDs are dated many decade...

journal_title：Current pharmaceutical design

authors： Chazapi E,Magoulas GE,Prousis KC,Calogeropoulou T

更新日期：2020-12-09 00:00:00

abstract：:In order to develop an effective pharmacological treatment for obesity, an endogenous factor that promotes a positive energy balance by increasing appetite and decreasing fat oxidation could represent the drug target scientists have been looking for. The recently discovered gastric endocrine agent ghrelin, which appea...

journal_title：Current pharmaceutical design

authors： Horvath TL,Castañeda T,Tang-Christensen M,Pagotto U,Tschöp MH

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Atherosclerosis is a chronic inflammatory disease and a leading cause of coronary artery disease, peripheral vascular disease and stroke. Lipid-laden macrophages are derived from circulating monocytes and form fatty streaks as the first step of atherogenesis. METHODS:An electronic search in major databases ...

journal_title：Current pharmaceutical design

authors： Taghizadeh E,Taheri F,Renani PG,Reiner Ž,Navashenaq JG,Sahebkar A

更新日期：2019-01-01 00:00:00

abstract：:Cardiovascular disease remains the number one killer in the United States and many other countries. Each year, there are enormous research efforts on its pathogenesis, prevention and treatment led by scientists worldwide. One of the most significant research areas is the impact and mechanisms of existing or new cardio...

journal_title：Current pharmaceutical design

authors： Jamaluddin MS,Liang Z,Lu JM,Yao Q,Chen C

更新日期：2014-01-01 00:00:00

abstract：:The brain is a complex, regulated organ with a highly controlled access mechanism: The Blood-Brain Barrier (BBB). The selectivity of this barrier is a double-edged sword, being both its greatest strength and weakness. This weakness is evident when trying to target therapeutics against diseases within the brain. Diseas...

journal_title：Current pharmaceutical design

authors： McCully M,Sanchez-Navarro M,Teixido M,Giralt E

更新日期：2018-01-01 00:00:00

abstract：:Glucocorticoids are the first line medication used in the therapy of many severe inflammatory disorders. They exert their activity through binding to the glucocorticoid receptor, a ligand-dependent transcription factor, and result in either activation or repression of a large set of glucocorticoid responsive genes. Th...

journal_title：Current pharmaceutical design

authors： Schulz M,Eggert M

更新日期：2004-01-01 00:00:00

abstract：:The metabolic syndrome (MetS) represents a cluster of medical disorders, such as hyperglycemia, dyslipidemia, hypertension, and abdominal obesity that, when occurring together, increase the risk of developing cardiovascular disease. The role of food and nutrients in the aetiology of chronic diseases has become clearer...

journal_title：Current pharmaceutical design

authors： Grosso G,Mistretta A,Marventano S,Purrello A,Vitaglione P,Calabrese G,Drago F,Galvano F

更新日期：2014-01-01 00:00:00

abstract：:Atherosclerosis is a multifactorial and long-lasting process in humans. Therefore, animal models where more rapid changes occur can be useful for the study of this process. Among such models are the apolipoprotein (apo) E knock out mice. Apo E deficient mice show impaired clearing of plasma lipoproteins and they devel...

journal_title：Current pharmaceutical design

authors： Kolovou G,Anagnostopoulou K,Mikhailidis DP,Cokkinos DV

更新日期：2008-01-01 00:00:00

abstract：:This review describes recent advances in the development of DNA-photocleavage agents. Major mechanisms of photosensitized DNA photocleavage are presented and the most popular categories of compounds are considered, which include metal complexes and many organic functional derivatives. DNA-targeted conjugates of photos...

journal_title：Current pharmaceutical design

authors： Da Ros T,Spalluto G,Boutorine AS,Bensasson RV,Prato M

更新日期：2001-11-01 00:00:00

abstract：:Drug development for neurodegenerative diseases such as Alzheimer's disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developi...

journal_title：Current pharmaceutical design

authors： Gomes B,Loureiro JA,Coelho MA,Pereira Mdo C

更新日期：2015-01-01 00:00:00

abstract：:Radiolabelled peptides and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation with clinical implications for several chronic inflammatory disorders for diagnosis, therapy decision making and follow up. In the last decades, a number of novel monoclonal antibodies and peptides h...

journal_title：Current pharmaceutical design

authors： Malviya G,Signore A,Laganà B,Dierckx RA

更新日期：2008-01-01 00:00:00

abstract：:Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w/v) propofol, ...

journal_title：Current pharmaceutical design

authors： Marik PE

更新日期：2004-01-01 00:00:00

abstract：:Rapid increase in the emergence and spread of microbes resistant to conventionally used antibiotics has become a major threat to global health care. Antimicrobial peptides (AMPs) are considered as a potential source of novel antibiotics because of their numerous advantages such as broad-spectrum activity, lower tenden...

journal_title：Current pharmaceutical design

authors： Lohan S,Bisht GS

更新日期：2013-01-01 00:00:00

abstract：:A better knowledge of the mechanisms underlying hepatocellular carcinoma (HCC) growth and spread is essential to improve the available treatment options. So far, the only therapies available for HCC are mainly based on tumor-destructive approaches, whereas no therapies are available to consolidate these invasive thera...

journal_title：Current pharmaceutical design

authors： Antonaci S,Giannelli G

更新日期：2007-01-01 00:00:00

abstract：:Monocytes are leading component of the mononuclear phagocytic system that play a key role in phagocytosis and removal of several kinds of microbes from the body. Monocytes are bone marrow precursor cells that stay in the blood for a few days and migrate towards tissues where they differentiate into macrophages. Monocy...

journal_title：Current pharmaceutical design

authors： Sabir F,Farooq RK,Asim Ur Rehman,Ahmed N

更新日期：2018-01-01 00:00:00

abstract：:HIV infection remains incurable although several anti-HIV drugs have been identified and developed. Among these the nucleoside analogues were and remain in the forefront of anti-HIV chemotherapeutic regimens. Most of these nucleoside analogues are modified mainly in the sugar moiety. In general, they lack a free hydro...

journal_title：Current pharmaceutical design

authors： el Kouni MH

更新日期：2002-01-01 00:00:00

abstract：:Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the ...

journal_title：Current pharmaceutical design

authors： Schaefer JR

更新日期：2011-01-01 00:00:00

abstract：:Over the last several years, it has become increasingly clear that dendritic cells (DC) are not only critical for the initiation of T cell immunity, but these cells also determine the course of the subsequent immune response (i.e. tolerance vs. immunity, Th1 vs. Th2). However, the mechanisms by which DC can influence ...

journal_title：Current pharmaceutical design

authors： Wan Y,Bramson J

更新日期：2001-07-01 00:00:00

abstract：:Cytokines are glycoproteins that serve as chemical messengers between cells. They assist in the regulation of cell growth and repair and also have immune modulating properties. Cytokines play a role in diverse clinical processes and phenomena such as fatigue, fever, sleep, pain, stress and aching. A review of the fibr...

journal_title：Current pharmaceutical design

authors： Wallace DJ

更新日期：2006-01-01 00:00:00

abstract：:Tumor necrosis factor alpha (TNF-α) is a multi-functional cytokine that regulates a variety of signaling pathways implicated in inflammation, immunity, cell death (apoptosis), cell survival (anti-apoptosis), and even tumorigenesis. TNF-α is predominantly produced by macrophages (or Kupffer cells within the liver), but...

journal_title：Current pharmaceutical design

authors： Jang MK,Kim HS,Chung YH

更新日期：2014-01-01 00:00:00

abstract：:The vasoconstrictive and antidiuretic physiologic properties of vasopressin (antidiuretic hormone) have long been known. Until recently however, vasopressin was mostly used for diabetes insipidus and noctournal enuresis. This review summarizes the growing body of evidence regarding the perioperative use of vasopressin...

journal_title：Current pharmaceutical design

authors： Udeh CI,Diaz-Gómez JL,Anthony D,Satyapriya A,Perez-Protto S,Hata JS

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND & AIMS:Nowadays, the world is facing a common problem that the population aging process is accelerating. How to delay metabolic disorders in middle-aged and elderly people, has become a hot scientific and social issue worthy of attention. The liver plays an important role in lipid metabolism, and abnormal li...

journal_title：Current pharmaceutical design

authors： Su H,Liu D,Shao J,Li Y,Wang X,Gao Q

更新日期：2020-01-01 00:00:00

abstract：:First generation drug-eluting stents (DES) have significantly improved the treatment options for patients with symptomatic coronary artery disease by decreasing rates of acute vessel closure and restenosis after percutaneous coronary revascularization procedures. However, early enthusiasm was temperd by reports of lat...

journal_title：Current pharmaceutical design

authors： Vorpahl M,Yazdani SK,Nakano M,Ladich E,Kolodgie FD,Finn AV,Virmani R

更新日期：2010-01-01 00:00:00

abstract：:Reduction strategies of blood pressure, as a modifiable cardiovascular risk, are currently based on office assessment of brachial artery blood pressure. However, antihypertensive treatment based on brachial BP values reduces cardiovascular risk but cannot completely reverse the hypertension-induced risk of morbidity e...

journal_title：Current pharmaceutical design

authors： Rinaldi ER,Yannoutsos A,Borghi C,Safar ME,Blacher J

更新日期：2015-01-01 00:00:00

abstract：:Nucleosides constitute an extensive group of natural and chemically modified compounds that display a wide range of structures and activities. Different biocatalysts have been developed for their preparation, but the choice of commercially available enzymes is limited. Therefore, the search of new biocatalysts is part...

journal_title：Current pharmaceutical design

authors： Lewkowicz ES,Iribarren AM

更新日期：2017-10-11 00:00:00

abstract：BACKGROUND:Erectile dysfunction (ED) is an evolving health problem in the aging male population. Chronic low-grade inflammation is a critical component of ED pathogenesis and a probable intermediate stage of endothelial dysfunction, especially in metabolic diseases, with the inclusion of obesity, metabolic syndrome, an...

journal_title：Current pharmaceutical design

authors： Kaya-Sezginer E,Gur S

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

journal_title：Current pharmaceutical design

authors： Iorio A,Guercini F,Ferrante F,Nenci GG

更新日期：2005-01-01 00:00:00

abstract：:Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis...

journal_title：Current pharmaceutical design

authors： McCreary AC,Newman-Tancredi A

更新日期：2015-01-01 00:00:00

abstract：:The integrin family of cell surface receptors were principally thought to be involved in cell adhesion. Intense study has shown that these glycoproteins also regulate a diverse range of physiological processes. Inappropriate activation of integrins has been implicated in many pathological processes. Recent studies hav...

journal_title：Current pharmaceutical design

authors： Robertson JH,Iga AM,Sales KM,Winslet MC,Seifalian AM

更新日期：2008-01-01 00:00:00